Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | MANBA | O00462 | 1/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931003 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL813413 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL2466059 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL21698544 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL4444890 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL468717 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL15858 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL6669482 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL592850 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL15630 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119909060-A | Application of xylolactone in preparation of drugs for enhancing proliferation capacity of male germ cells | 中国农业科学院油料作物研究所 | 2025-05-02 | — | — | CN | claimed |
| US-20240057589-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC | 2024-02-22 | — | — | US | claimed |
| CN-109312373-B | Microorganisms and methods for co-production of ethylene glycol and three carbon compounds | 布拉斯肯有限公司 | 2022-07-19 | — | — | CN | claimed |
| WO-2022146771-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC (US) | 2022-07-07 | — | — | WO | claimed |
| CN-114686532-A | Method for the enzymatic production of oxidation products and reduction products of mixed sugars | 安尼基有限责任公司 | 2022-07-01 | — | — | CN | claimed |
| EP-4739784-A1 | METHOD FOR PRODUCING AN AQUEOUS SOLUTION CONTAINING ETHYLENE GLYCOL | Annikki GmbH (AT) | 2026-05-13 | — | — | EP | disclosed |
| US-12584151-B1 | Modified microorganisms to increase yield of xylose-derived products | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4658802-A1 | PROCESS FOR MAKING DRIMANE ALDEHYDES | Firmenich SA (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-12486513-B2 | Modulation of carbon flux through the meg and C3 pathways for the improved production of monoethylene glycol and C3 compounds | BRASKEM S.A. (BR) | 2025-12-02 | — | — | US | disclosed |
| US-12447118-B2 | Hair treatment compositions | CONOPCO, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-1956929-A2 | AN EDIBLE COMPOSITION | DANISCO A/S (DK) | 2008-08-20 | — | — | EP | disclosed |
| EP-1940348-A2 | A COMPOSITION COMPRISING A COUPLED ENZYME SYSTEM | DANISCO A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045251-A2 | A COMPOSITION COMPRISING A COUPLED ENZYME SYSTEM | DANISCO A/S (DK) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045252-A2 | AN EDIBLE COMPOSITION | DANISCO A/S (DK) | 2007-04-26 | — | — | WO | disclosed |
| EP-0897977-B1 | Enzyme complex | HOFFMANN LA ROCHE (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-0897977-A2 | Enzyme complex | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
| EP-0325190-A2 | Pentosansulfate medium | Roche Diagnostics GmbH (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4064277-A | SOYBEAN MILK, BETA-GLYCOSIDASE | KIKKOMAN SHOYU CO., LTD. (JA) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447118-B2 | Hair treatment compositions | SLC25A1, OAT, OTC | LMNA 1965/4885GBA1 4159/4885DNMT1 839/4885 |
| US-12584151-B1 | Modified microorganisms to increase yield of xylose-derived products | DCXR, XDH, TDO2 | LMNA 3376/4885GBA1 3253/4885DNMT1 2342/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | LMNA 2887/4885GBA1 4613/4885DNMT1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.